Literature DB >> 35586429

Novel BTK Inhibitors for Treating Autoimmune Disorders and Cancer.

Ram W Sabnis1.   

Abstract

Entities:  

Year:  2022        PMID： 35586429      PMCID： PMC9109420          DOI： 10.1021/acsmedchemlett.2c00143

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  5 in total

Review 1.  Recent development of BTK-based dual inhibitors in the treatment of cancers.

Authors:  Fansheng Ran; Yun Liu; Zhongyuan Xu; Chi Meng; Dezhi Yang; Jianqiang Qian; Xuexian Deng; Yanan Zhang; Yong Ling
Journal:  Eur J Med Chem       Date:  2022-02-25       Impact factor: 6.514

Review 2.  Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update.

Authors:  Robert Roskoski
Journal:  Pharmacol Res       Date:  2021-01-26       Impact factor: 7.658

Review 3.  Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies.

Authors:  Deborah M Stephens; John C Byrd
Journal:  Blood       Date:  2021-09-30       Impact factor: 25.476

Review 4.  Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Beyond Ibrutinib.

Authors:  Masa Lasica; Constantine S Tam
Journal:  Hematol Oncol Clin North Am       Date:  2021-05-28       Impact factor: 3.722
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.